InnoCare Pharma (INCPF) Expected to Post Earnings on Monday

InnoCare Pharma (OTCMKTS:INCPF – Get Free Report) is expected to release its resultson Monday, October 26th. Analysts expect InnoCare Pharma to post earnings of ($0.0385) per share and revenue of $23.00 million for the quarter.

InnoCare Pharma Stock Performance

Shares of OTCMKTS INCPF opened at $1.60 on Friday. InnoCare Pharma has a 12-month low of $1.60 and a 12-month high of $1.85. The stock has a fifty day moving average price of $1.62 and a 200 day moving average price of $1.57.

About InnoCare Pharma

(Get Free Report)

InnoCare Pharma Limited is a biopharmaceutical company focused on discovering, developing and commercializing innovative medicines for cancer and autoimmune diseases. The company conducts research in areas including targeted therapies, immuno-oncology and treatments designed to address significant unmet medical needs.

Its primary commercial product is orelabrutinib, a highly selective Bruton’s tyrosine kinase inhibitor marketed in China for certain B-cell malignancies, including mantle cell lymphoma and chronic lymphocytic leukemia or small lymphocytic lymphoma.

Further Reading

• Five stocks we like better than InnoCare Pharma
• Bloom Energy Just Reported—Its Biggest Order Is Still Waiting on a Pipeline
• Why Western Digital’s AI Storage Boom Defies the Chip Sell-Off
• Grand Canyon Education Strengthens Its Outlook, But Wall Street Remains Divided
• Amex Stock Slides on Job Cuts, But the Real Story Is Macro